COMMUNIQUÉS West-GlobeNewswire

TELA Bio Reports Second Quarter 2025 Financial Results
11/08/2025
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
11/08/2025
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S. clinical trials, including [...]
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
11/08/2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be [...]
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
11/08/2025
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo [...]
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
11/08/2025
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway Expected to Support [...]
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
11/08/2025
Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive Chairman, appointed interim CEO [...]
Xenon Reports Second Quarter 2025 Financial Results & Business Update
11/08/2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently [...]
Harrow Announces Second-Quarter 2025 Financial Results
11/08/2025
Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net income of $5.0 million Adjusted EBITDA of $17.0 million [...]
Standard BioTools Reports Second Quarter 2025 Financial Results
11/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. [...]
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
11/08/2025
FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026 Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDA Company accelerates Anaphylm global expansion strategy to [...]
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results
11/08/2025
Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclib OPERA-01 enrollment ongoing with top-line data expected in [...]
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
11/08/2025
Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development [...]
Inventiva Participera à la « Canaccord Genuity 45th Annual Growth Conference »
11/08/2025
Daix (France), New York City (New York, Etats-Unis), le 11 aout 2025 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
11/08/2025
WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN ), reiterates investor confidence and estimated asset value over $10 billion. In October 2024, HMP [...]
Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients
11/08/2025
Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health , a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 [...]
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
11/08/2025
Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2. Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five [...]
Esteworld Opens First UK Representative Office in London’s Covent Garden
11/08/2025
Photo: Esteworld Opens Its First Representative Office in the UK in London LONDON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Turkish aesthetic healthcare group Esteworld has strengthened its presence in the UK market with the [...]
BHIANT Quarterly Update: North Texas Bio Innovation Gains Momentum with Workforce Development and Industry Collaboration
11/08/2025
DALLAS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- BHIANT , the workforce development arm of BioNTX, is charting new ground in biotechnology talent development and industry collaboration, strengthening North Texas’ position as a [...]
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
11/08/2025
Total eligible patients in the US exceed 2 million. Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment. Reflects business philosophy of commercial success through patient [...]

Pages